A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
The team showed the approach could successfully monitor cytokines in infants after heart surgery, and is involved now in a larger clinical study expanding this research.
British biotechnology firm QuantuMDx last week announced an agreement with the Genome Institute of Singapore that will see the partners develop a genetic test specific to Asian populations on QuantuMDx's nanowire array-based platform.
NEW YORK (GenomeWeb News) – Mediomics has reeled in a $997,251 grant from the National Cancer Institute to continue developing technologies for monitoring the titer and quality of recombinant biologics, the company said today.
Attana recently announced that it has been certified according to the International Organization for Standardization's 9001:2008 quality management systems standard.
Biomagnetics Diagnostics intends to develop a handheld, integrated optical biosensor for rapid diagnosis of HIV/AIDS, malaria, tuberculosis, and other pathogens.
STC.UNM, the technology-transfer arm for UNM, was lead institution on the agreement, under which Adaptive Methods may obtain an exclusive license to manufacture and sell a variety of products incorporating the biosensor technology.
Pfizer and UCL to develop stem-cell therapies for AMD; Clarient licenses breast cancer biomarkers from Indiana U; Nanosys and Harvard to outlicense nanowire IP; Luminex settles with SUNY and U of Illinois, and more …
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.
